Genzyme Sues Over Endo's Bid To Sell Generic Renvela

Law360, New York (April 27, 2011, 8:24 PM EDT) -- Genzyme Corp. on Wednesday filed suit in Maryland accusing Endo Pharmaceuticals Inc. of infringing its patent covering Renvela by seeking approval to sell a generic version of the kidney disease treatment before the patent expires.

Genzyme claims Endo submitted an abbreviated new drug application to the U.S. Food and Drug Administration that infringes the claims of Genzyme's U.S. Patent No. 5,667,775, which covers phosphate-binding polymers for oral administration and is used to treat patients with chronic kidney disease on dialysis.

Genzyme has aggressively sought to protect...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.